- Home
- Automated
- List of product information
- AROMASIN TABLET 25MG [SIN11398P]
AROMASIN TABLET 25MG [SIN11398P]
Active ingredients: AROMASIN TABLET 25MG
Last updated 26 October 2025
On this page
Product Info
AROMASIN TABLET 25MG
[SIN11398P]
Product information
Active Ingredient and Strength | EXEMESTANE - 25 MG |
Dosage Form | TABLET, SUGAR COATED |
Manufacturer and Country | PFIZER ITALIA S.R.L. - ITALY |
Registration Number | SIN11398P |
Licence Holder | PFIZER PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | L02BG06 |
4.1. Therapeutic Indications
Exemestane is indicated for the adjuvant treatment of post-menopausal women with estrogen-receptor positive invasive early breast cancer, following 2–3 years of initial adjuvant tamoxifen therapy.
Exemestane is indicated for the treatment of advanced breast cancer in women with natural or induced post-menopausal status whose disease has progressed following anti-estrogen therapy.
4.2. Posology and Method of Administration
Adult and Elderly Patients
The recommended dose of exemestane is one 25 mg tablet to be taken once daily, preferably after a meal.
In patients with early breast cancer, treatment with exemestane should continue until completion of five years of combined sequential adjuvant hormonal therapy (tamoxifen followed by exemestane), or earlier if tumour relapse occurs.
In patients with advanced breast cancer, treatment with exemestane should continue until tumor progression is evident.
Hepatic or Renal Insufficiency
No dose adjustments are required for patients with hepatic or renal insufficiency.
Children
Not recommended for use in children.
4.3. Contraindications
Exemestane is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.